JP2013512926A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013512926A5 JP2013512926A5 JP2012542219A JP2012542219A JP2013512926A5 JP 2013512926 A5 JP2013512926 A5 JP 2013512926A5 JP 2012542219 A JP2012542219 A JP 2012542219A JP 2012542219 A JP2012542219 A JP 2012542219A JP 2013512926 A5 JP2013512926 A5 JP 2013512926A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- optionally substituted
- disorder
- alkyl
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 82
- 125000000623 heterocyclic group Chemical group 0.000 claims 21
- 125000004429 atom Chemical group 0.000 claims 20
- 229910052739 hydrogen Inorganic materials 0.000 claims 16
- 239000001257 hydrogen Substances 0.000 claims 16
- 125000003118 aryl group Chemical group 0.000 claims 14
- 125000001072 heteroaryl group Chemical group 0.000 claims 14
- 125000000753 cycloalkyl group Chemical group 0.000 claims 13
- 150000002431 hydrogen Chemical class 0.000 claims 12
- 125000000217 alkyl group Chemical group 0.000 claims 11
- 125000003545 alkoxy group Chemical group 0.000 claims 10
- 125000004103 aminoalkyl group Chemical group 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 10
- 208000028017 Psychotic disease Diseases 0.000 claims 8
- 125000003342 alkenyl group Chemical group 0.000 claims 8
- 125000000304 alkynyl group Chemical group 0.000 claims 8
- 125000003710 aryl alkyl group Chemical group 0.000 claims 8
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 8
- -1 nitro, amino, hydroxyl Chemical group 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 208000035475 disorder Diseases 0.000 claims 6
- 201000000980 schizophrenia Diseases 0.000 claims 6
- 229910052757 nitrogen Inorganic materials 0.000 claims 5
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 125000005843 halogen group Chemical group 0.000 claims 4
- 125000003107 substituted aryl group Chemical group 0.000 claims 4
- 208000019022 Mood disease Diseases 0.000 claims 3
- 208000017194 Affective disease Diseases 0.000 claims 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 2
- 208000023105 Huntington disease Diseases 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 206010041349 Somnolence Diseases 0.000 claims 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 2
- 230000003796 beauty Effects 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 206010015037 epilepsy Diseases 0.000 claims 2
- 208000022821 personality disease Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 230000000698 schizophrenic effect Effects 0.000 claims 2
- 208000011117 substance-related disease Diseases 0.000 claims 2
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 2
- 206010001497 Agitation Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 206010003805 Autism Diseases 0.000 claims 1
- 208000020706 Autistic disease Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 206010010904 Convulsion Diseases 0.000 claims 1
- 102000012437 Copper-Transporting ATPases Human genes 0.000 claims 1
- 206010012218 Delirium Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 206010012335 Dependence Diseases 0.000 claims 1
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 claims 1
- 206010013654 Drug abuse Diseases 0.000 claims 1
- 208000012661 Dyskinesia Diseases 0.000 claims 1
- 208000030814 Eating disease Diseases 0.000 claims 1
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 1
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims 1
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010065390 Inflammatory pain Diseases 0.000 claims 1
- 208000001456 Jet Lag Syndrome Diseases 0.000 claims 1
- 208000009625 Lesch-Nyhan syndrome Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 208000016285 Movement disease Diseases 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 1
- 208000027099 Paranoid disease Diseases 0.000 claims 1
- 208000005793 Restless legs syndrome Diseases 0.000 claims 1
- 206010070834 Sensitisation Diseases 0.000 claims 1
- 201000001880 Sexual dysfunction Diseases 0.000 claims 1
- 208000019568 Shared Paranoid disease Diseases 0.000 claims 1
- 208000028810 Shared psychotic disease Diseases 0.000 claims 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims 1
- 208000032140 Sleepiness Diseases 0.000 claims 1
- 208000011963 Substance-induced psychotic disease Diseases 0.000 claims 1
- 231100000393 Substance-induced psychotic disorder Toxicity 0.000 claims 1
- 208000000323 Tourette Syndrome Diseases 0.000 claims 1
- 208000016620 Tourette disease Diseases 0.000 claims 1
- 206010047700 Vomiting Diseases 0.000 claims 1
- 208000018839 Wilson disease Diseases 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 230000016571 aggressive behavior Effects 0.000 claims 1
- 238000013019 agitation Methods 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 230000003542 behavioural effect Effects 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 208000002173 dizziness Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010013663 drug dependence Diseases 0.000 claims 1
- 201000002545 drug psychosis Diseases 0.000 claims 1
- 208000024732 dysthymic disease Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000002964 excitative effect Effects 0.000 claims 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims 1
- 206010022437 insomnia Diseases 0.000 claims 1
- 208000033915 jet lag type circadian rhythm sleep disease Diseases 0.000 claims 1
- 208000024714 major depressive disease Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000003340 mental effect Effects 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 230000036651 mood Effects 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 201000003631 narcolepsy Diseases 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 230000007170 pathology Effects 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 1
- 208000012672 seasonal affective disease Diseases 0.000 claims 1
- 230000008313 sensitization Effects 0.000 claims 1
- 231100000872 sexual dysfunction Toxicity 0.000 claims 1
- 201000002859 sleep apnea Diseases 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 208000020685 sleep-wake disease Diseases 0.000 claims 1
- 230000037321 sleepiness Effects 0.000 claims 1
- 238000001228 spectrum Methods 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 230000008673 vomiting Effects 0.000 claims 1
- 0 CNC[C@](c1c(CC*)[s]c(F)c1)O Chemical compound CNC[C@](c1c(CC*)[s]c(F)c1)O 0.000 description 25
- AITUYMATOVBOMM-UHFFFAOYSA-N C=Cc1c[s]c2c1C(CN)C(C1)C1CC2 Chemical compound C=Cc1c[s]c2c1C(CN)C(C1)C1CC2 AITUYMATOVBOMM-UHFFFAOYSA-N 0.000 description 1
- NIBDYNBWJDEMKA-UHFFFAOYSA-N CC1(CN)OCCc2c1cc[s]2 Chemical compound CC1(CN)OCCc2c1cc[s]2 NIBDYNBWJDEMKA-UHFFFAOYSA-N 0.000 description 1
- WEFZFBQIYMCFNU-VIFPVBQESA-N CCNC[C@@H]1OCCc2c1cc[s]2 Chemical compound CCNC[C@@H]1OCCc2c1cc[s]2 WEFZFBQIYMCFNU-VIFPVBQESA-N 0.000 description 1
- WEFZFBQIYMCFNU-SECBINFHSA-N CCNC[C@H]1OCCc2c1cc[s]2 Chemical compound CCNC[C@H]1OCCc2c1cc[s]2 WEFZFBQIYMCFNU-SECBINFHSA-N 0.000 description 1
- INRPJRPERXJBQV-UHFFFAOYSA-N CNC1(CCCCC1)C(CCC1)c2c1[s]cc2 Chemical compound CNC1(CCCCC1)C(CCC1)c2c1[s]cc2 INRPJRPERXJBQV-UHFFFAOYSA-N 0.000 description 1
- POTLHQVUZAJAMW-UHFFFAOYSA-N CNC1(CCCCC1)C1OCCc2c1cc[s]2 Chemical compound CNC1(CCCCC1)C1OCCc2c1cc[s]2 POTLHQVUZAJAMW-UHFFFAOYSA-N 0.000 description 1
- ZQPHNVQEKLGCPX-UHFFFAOYSA-N CNCC(C(C1)C1CC1)c2c1[s]c(cc1Cl)c2cc1Cl Chemical compound CNCC(C(C1)C1CC1)c2c1[s]c(cc1Cl)c2cc1Cl ZQPHNVQEKLGCPX-UHFFFAOYSA-N 0.000 description 1
- FVTQFFKKJVXMEI-UHFFFAOYSA-N CNCC(C1)OCCc2c1c(cccc1)c1[s]2 Chemical compound CNCC(C1)OCCc2c1c(cccc1)c1[s]2 FVTQFFKKJVXMEI-UHFFFAOYSA-N 0.000 description 1
- XYUVIJDAKOOBHM-UHFFFAOYSA-N CNCC1OCCCc2c1c(cc(cc1)Cl)c1[s]2 Chemical compound CNCC1OCCCc2c1c(cc(cc1)Cl)c1[s]2 XYUVIJDAKOOBHM-UHFFFAOYSA-N 0.000 description 1
- OZZOPYQBYKNRLX-BYDSUWOYSA-N C[C@@H](C1OCCc2c1cc[s]2)NC Chemical compound C[C@@H](C1OCCc2c1cc[s]2)NC OZZOPYQBYKNRLX-BYDSUWOYSA-N 0.000 description 1
- OZZOPYQBYKNRLX-OIBJUYFYSA-N C[C@@H]([C@H]1OCCc2c1cc[s]2)NC Chemical compound C[C@@H]([C@H]1OCCc2c1cc[s]2)NC OZZOPYQBYKNRLX-OIBJUYFYSA-N 0.000 description 1
- QRNNJKDCCSPWRW-SECBINFHSA-N C[C@H](Cc1c(CCC=C)[s]cc1)N Chemical compound C[C@H](Cc1c(CCC=C)[s]cc1)N QRNNJKDCCSPWRW-SECBINFHSA-N 0.000 description 1
- TYUOXKFOCVXJHQ-RKDXNWHRSA-N C[C@H]([C@@H](CCC1)c2c1[s]cc2)NC Chemical compound C[C@H]([C@@H](CCC1)c2c1[s]cc2)NC TYUOXKFOCVXJHQ-RKDXNWHRSA-N 0.000 description 1
- IDOCJOSQBZUOCM-VVESDKHQSA-N Cc1c(F)[s]c(CCC2)c1[C@H]2/C=N/C Chemical compound Cc1c(F)[s]c(CCC2)c1[C@H]2/C=N/C IDOCJOSQBZUOCM-VVESDKHQSA-N 0.000 description 1
- GTONKMHLSYUCMQ-QMMMGPOBSA-N Cc1c(F)[s]c2c1[C@H](CNC)CCC2 Chemical compound Cc1c(F)[s]c2c1[C@H](CNC)CCC2 GTONKMHLSYUCMQ-QMMMGPOBSA-N 0.000 description 1
- NCUVFQFEYGFGKF-UHFFFAOYSA-N Cc1c[s]c(CCCCC2)c1C2(C1)C1N Chemical compound Cc1c[s]c(CCCCC2)c1C2(C1)C1N NCUVFQFEYGFGKF-UHFFFAOYSA-N 0.000 description 1
- RQPKRDCFGLCWNM-UHFFFAOYSA-N NC1(CCCCC1)C1OCCc2c1cc[s]2 Chemical compound NC1(CCCCC1)C1OCCc2c1cc[s]2 RQPKRDCFGLCWNM-UHFFFAOYSA-N 0.000 description 1
- JWARAXKPSGYYFJ-UHFFFAOYSA-N NCC(C(C1)C1CC1)c2c1[s]c1ccc(C3[IH]C3)c(Cl)c21 Chemical compound NCC(C(C1)C1CC1)c2c1[s]c1ccc(C3[IH]C3)c(Cl)c21 JWARAXKPSGYYFJ-UHFFFAOYSA-N 0.000 description 1
- BYWRIADOSKHATA-UHFFFAOYSA-N NCC(C(CC1)C1CC1)C2=C1SC1C2CCC1 Chemical compound NCC(C(CC1)C1CC1)C2=C1SC1C2CCC1 BYWRIADOSKHATA-UHFFFAOYSA-N 0.000 description 1
- ZAUOAOTXDCDNGY-UHFFFAOYSA-N NCC(C(CC1)C1CC1)c2c1[s]c1c2cccc1Cl Chemical compound NCC(C(CC1)C1CC1)c2c1[s]c1c2cccc1Cl ZAUOAOTXDCDNGY-UHFFFAOYSA-N 0.000 description 1
- XCQJLLHUMDSONB-UHFFFAOYSA-N NCC(CCCC1)c2c1[s]cc2Cl Chemical compound NCC(CCCC1)c2c1[s]cc2Cl XCQJLLHUMDSONB-UHFFFAOYSA-N 0.000 description 1
- MKZGIOMVPDPCBC-UHFFFAOYSA-N NCC1OCCc([s]c2c3)c1c2cc(Cl)c3Cl Chemical compound NCC1OCCc([s]c2c3)c1c2cc(Cl)c3Cl MKZGIOMVPDPCBC-UHFFFAOYSA-N 0.000 description 1
- MGNDZEHNXZDELF-UHFFFAOYSA-N NCC1OCCc2c1c(CCC=C1)c1[s]2 Chemical compound NCC1OCCc2c1c(CCC=C1)c1[s]2 MGNDZEHNXZDELF-UHFFFAOYSA-N 0.000 description 1
- AZSVLAYHORYULP-UHFFFAOYSA-N NCC1OCCc2c1c(cc(C1[I]=CC1)cc1)c1[s]2 Chemical compound NCC1OCCc2c1c(cc(C1[I]=CC1)cc1)c1[s]2 AZSVLAYHORYULP-UHFFFAOYSA-N 0.000 description 1
- RDSQWIWOHKRUMG-VIFPVBQESA-N NC[C@@H]1OCCc2c1c(cccc1)c1[s]2 Chemical compound NC[C@@H]1OCCc2c1c(cccc1)c1[s]2 RDSQWIWOHKRUMG-VIFPVBQESA-N 0.000 description 1
- RDSQWIWOHKRUMG-SECBINFHSA-N NC[C@H]1OCCc2c1c1ccccc1[s]2 Chemical compound NC[C@H]1OCCc2c1c1ccccc1[s]2 RDSQWIWOHKRUMG-SECBINFHSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26688009P | 2009-12-04 | 2009-12-04 | |
| US61/266,880 | 2009-12-04 | ||
| PCT/US2010/058884 WO2011069063A2 (en) | 2009-12-04 | 2010-12-03 | Multicyclic compounds and methods of use thereof |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014253082A Division JP5710064B1 (ja) | 2009-12-04 | 2014-12-15 | 多環式化合物及びその使用方法 |
| JP2015136603A Division JP6005807B2 (ja) | 2009-12-04 | 2015-07-08 | 多環式化合物及びその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013512926A JP2013512926A (ja) | 2013-04-18 |
| JP2013512926A5 true JP2013512926A5 (enExample) | 2014-01-23 |
| JP5778168B2 JP5778168B2 (ja) | 2015-09-16 |
Family
ID=44115515
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012542219A Active JP5778168B2 (ja) | 2009-12-04 | 2010-12-03 | 多環式化合物及びその使用方法 |
| JP2014253082A Active JP5710064B1 (ja) | 2009-12-04 | 2014-12-15 | 多環式化合物及びその使用方法 |
| JP2015136603A Active JP6005807B2 (ja) | 2009-12-04 | 2015-07-08 | 多環式化合物及びその使用方法 |
| JP2016131247A Active JP6028310B1 (ja) | 2009-12-04 | 2016-07-01 | 多環式化合物及びその使用方法 |
| JP2016191898A Active JP6297655B2 (ja) | 2009-12-04 | 2016-09-29 | 多環式化合物及びその使用方法 |
| JP2018028819A Pending JP2018104454A (ja) | 2009-12-04 | 2018-02-21 | 多環式化合物及びその使用方法 |
| JP2020108727A Active JP7104746B2 (ja) | 2009-12-04 | 2020-06-24 | 多環式化合物及びその使用方法 |
Family Applications After (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014253082A Active JP5710064B1 (ja) | 2009-12-04 | 2014-12-15 | 多環式化合物及びその使用方法 |
| JP2015136603A Active JP6005807B2 (ja) | 2009-12-04 | 2015-07-08 | 多環式化合物及びその使用方法 |
| JP2016131247A Active JP6028310B1 (ja) | 2009-12-04 | 2016-07-01 | 多環式化合物及びその使用方法 |
| JP2016191898A Active JP6297655B2 (ja) | 2009-12-04 | 2016-09-29 | 多環式化合物及びその使用方法 |
| JP2018028819A Pending JP2018104454A (ja) | 2009-12-04 | 2018-02-21 | 多環式化合物及びその使用方法 |
| JP2020108727A Active JP7104746B2 (ja) | 2009-12-04 | 2020-06-24 | 多環式化合物及びその使用方法 |
Country Status (20)
| Country | Link |
|---|---|
| US (9) | US8710245B2 (enExample) |
| EP (2) | EP2507245B1 (enExample) |
| JP (7) | JP5778168B2 (enExample) |
| KR (7) | KR102505085B1 (enExample) |
| CN (5) | CN102762575B (enExample) |
| AU (3) | AU2010325925B2 (enExample) |
| BR (2) | BR112012013431B1 (enExample) |
| CA (2) | CA3272595A1 (enExample) |
| DK (2) | DK3252057T3 (enExample) |
| ES (2) | ES2978959T3 (enExample) |
| FI (1) | FI3252057T3 (enExample) |
| HK (1) | HK1212969A1 (enExample) |
| IL (6) | IL272376B2 (enExample) |
| MX (3) | MX388468B (enExample) |
| NZ (5) | NZ711802A (enExample) |
| PT (2) | PT3252057T (enExample) |
| RU (3) | RU2707067C2 (enExample) |
| SG (3) | SG10201401661RA (enExample) |
| WO (1) | WO2011069063A2 (enExample) |
| ZA (1) | ZA201203533B (enExample) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3252057T (pt) * | 2009-12-04 | 2024-06-04 | Sunovion Pharmaceuticals Inc | Compostos multicíclicos e métodos de utilização dos mesmos |
| WO2013066152A1 (en) * | 2011-10-31 | 2013-05-10 | N.V. Nutricia | Method for improving executive function |
| AU2013216935C1 (en) * | 2012-02-08 | 2017-12-14 | John Emmerson Campbell | Heteroaryl compounds and methods of use thereof |
| CN103755727B (zh) * | 2013-12-20 | 2015-12-30 | 南京华威医药科技开发有限公司 | 布林佐胺中间体制备方法 |
| WO2015112902A2 (en) * | 2014-01-23 | 2015-07-30 | Sova Pharmaceuticals, Inc. | CYSTATHIONINE-(gamma)-LYASE (CSE) INHIBITORS FOR TREATING PAIN |
| EP3186257B1 (en) | 2014-08-27 | 2019-02-06 | Prexton Therapeutics SA | Novel chromone oxime derivative and its use as allosteric modulator of metabotropic glutamate receptors |
| CN104193722A (zh) * | 2014-08-27 | 2014-12-10 | 湖南华腾制药有限公司 | 一种n-叔丁氧羰基-3-甲胺噻吩的制备方法 |
| AU2016219253C1 (en) * | 2015-02-11 | 2022-12-08 | Pgi Drug Discovery Llc | 1-heterocyclyl isochromanyl compounds and analogs for treating CNS disorders |
| CA2976092A1 (en) * | 2015-02-11 | 2016-08-18 | Sunovion Pharmaceuticals Inc. | Fused dihydro-4h-pyrazolo[5,1-c][1,4]oxazinyl compounds and analogs for treating cns disorders |
| WO2017032874A1 (en) | 2015-08-27 | 2017-03-02 | Prexton Therapeutics Sa | Brain-penetrant chromone oxime derivative for the therapy of levodopa-induced dyskinesia |
| JO3638B1 (ar) * | 2015-09-09 | 2020-08-27 | Lilly Co Eli | مركبات مفيدة في تثبيط ror - جاما- t |
| PT3407888T (pt) * | 2016-01-26 | 2021-03-19 | Intra Cellular Therapies Inc | Compostos de piridopirroloquinoxalina, suas composições e utilizações |
| WO2017144341A1 (de) | 2016-02-23 | 2017-08-31 | Bayer Cropscience Aktiengesellschaft | Kondensierte bicyclische heterocyclen-derivate als schädlingsbekämpfungsmittel |
| MX2019000982A (es) | 2016-07-29 | 2019-07-04 | Sunovion Pharmaceuticals Inc | Compuestos y composiciones y usos de los mismos. |
| EA201990400A1 (ru) | 2016-07-29 | 2019-07-31 | Суновион Фармасьютикалз, Инк. | Соединения и композиции и их применение |
| CN116808023A (zh) * | 2017-02-16 | 2023-09-29 | 桑诺维恩药品公司 | 治疗精神分裂症的方法 |
| WO2018166855A1 (en) | 2017-03-16 | 2018-09-20 | Basf Se | Heterobicyclic substituted dihydroisoxazoles |
| JP7191085B2 (ja) | 2017-08-02 | 2022-12-16 | サノビオン ファーマシューティカルズ インク | イソクロマン化合物およびその使用 |
| JP2021513972A (ja) * | 2018-02-16 | 2021-06-03 | サノビオン ファーマシューティカルズ インクＳｕｎｏｖｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． | 社会的機能障害の治療方法 |
| MX2020008537A (es) * | 2018-02-16 | 2021-01-08 | Sunovion Pharmaceuticals Inc | Sales, formas cristalinas y metodos de produccion de las mismas. |
| CA3122261A1 (en) * | 2018-12-06 | 2020-06-11 | Sunovion Pharmaceuticals Inc. | Methods of treating neurological and psychiatric disorders |
| CN113784755B (zh) | 2019-03-14 | 2024-05-10 | 赛诺维信制药公司 | 异色满基化合物的盐及其结晶形式、制备方法、治疗用途和药物组合物 |
| CN110894195A (zh) * | 2019-12-09 | 2020-03-20 | 门希国 | 一种新的2-噻吩乙酸的制备新方法 |
| EP4125840A1 (en) | 2020-03-27 | 2023-02-08 | Som Innovation Biotech, S.A. | Compounds for use in the treatment of synucleinopathies |
| CA3180115A1 (en) * | 2020-04-14 | 2021-10-21 | Sunovion Pharmaceuticals Inc. | (s)-(4,5-dihydro-7h-thieno[2,3-c]pyran-7-yl)-n-methylmethanamine for treating neurological and psychiatric disorders |
| EP4214212A1 (en) | 2020-09-16 | 2023-07-26 | Teva Pharmaceuticals International GmbH | Solid state forms of sep-363856 and process for preparation thereof |
| TWI836390B (zh) * | 2021-03-29 | 2024-03-21 | 大陸商上海樞境生物科技有限公司 | 含螺環類衍生物、其製備方法和應用 |
| CN117177977A (zh) * | 2021-04-10 | 2023-12-05 | 住友制药株式会社 | 二环吡啶衍生物 |
| US12077546B2 (en) | 2021-04-10 | 2024-09-03 | Sumitomo Pharma Co., Ltd. | Bicyclic pyridine derivative |
| BR112023020924A2 (pt) * | 2021-04-10 | 2024-02-15 | Sumitomo Pharma Co Ltd | Derivado de piridina bicíclica |
| CN115677718B (zh) * | 2021-07-30 | 2024-11-01 | 武汉思瓴生物科技有限公司 | 甲基甲胺类衍生物制剂、药物组合物及其应用 |
| US20230241024A1 (en) | 2021-09-23 | 2023-08-03 | Sunovion Pharmaceuticals Inc. | Methods of treating metabolic disorders |
| EP4428128A4 (en) | 2021-11-04 | 2026-01-07 | Shanghai Hansoh Biomedical Co Ltd | 2-(ARYL-2-YL)MORPHOLINE AND DEUTERATED DERIVATIVE THEREOF, ITS PREPARATION PROCESS AND ITS APPLICATION |
| CN114324369B (zh) * | 2022-03-11 | 2022-06-07 | 北京新研创能科技有限公司 | 双极板表面划痕检测系统及方法 |
| KR20250028295A (ko) * | 2022-06-24 | 2025-02-28 | 산동 루예 파마슈티칼 컴파니 리미티드 | Taar1 리간드 작용제로서의 헤테로고리 화합물 |
| AU2023334027A1 (en) | 2022-08-30 | 2025-01-09 | Sumitomo Pharma America, Inc. | Ulotaront for the adjuvant treatment of major depressive disorder |
| CN117777157B (zh) * | 2022-09-27 | 2026-04-28 | 上海枢境生物科技有限公司 | 含螺环类衍生物的盐、晶型及其制备方法和应用 |
| EP4596556A4 (en) * | 2022-09-27 | 2025-12-10 | Shujing Biopharma Co Ltd | SALT OR CRYSTALLINE FORM CONTAINING A SPIROCYCLICAL DERIVATIVE, ITS PREPARATION PROCESS AND ITS USE |
| EP4601634A1 (en) | 2022-10-13 | 2025-08-20 | Sumitomo Pharma America, Inc. | Methods of reducing physical dependence to neuropsychiatric treatments |
| CN115677719B (zh) * | 2022-10-27 | 2025-03-07 | 复旦大学 | 一种芳基并杂环化合物及其制备方法和用途 |
| AU2023367071A1 (en) | 2022-10-28 | 2025-06-12 | Sumitomo Pharma America, Inc. | Ulotaront for treating anxiety and associated conditions |
| JP2025538225A (ja) | 2022-11-15 | 2025-11-26 | スミトモ・ファーマ・アメリカ・インコーポレイテッド | 神経精神病薬を切り替える方法 |
| CN120418254A (zh) * | 2022-12-09 | 2025-08-01 | 上海枢境生物科技有限公司 | 并环类衍生物、其制备方法、中间体和应用 |
| WO2025097104A1 (en) * | 2023-11-02 | 2025-05-08 | Pgi Drug Discovery Llc | Thienyl compounds for the treatment of a central nervous system disease or disorder |
| WO2025131045A1 (zh) * | 2023-12-22 | 2025-06-26 | 山东绿叶制药有限公司 | 一种taar1配体激动剂的盐型、晶型及其制备方法和应用 |
| US20250262185A1 (en) | 2024-02-16 | 2025-08-21 | Sumitomo Pharma America, Inc. | Methods of administering neuropsychiatric medications based on renal impairment |
| TW202600129A (zh) | 2024-02-23 | 2026-01-01 | 美商住友製藥美國公司 | 烏洛托隆（ulotaront）鹽酸鹽的製造方法 |
Family Cites Families (141)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US402145A (en) * | 1889-04-30 | Combined trough and rack | ||
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US4021451A (en) * | 1972-05-16 | 1977-05-03 | American Home Products Corporation | Process for preparing polycyclic heterocycles having a pyran ring |
| US4036842A (en) * | 1972-05-16 | 1977-07-19 | American Home Products Corporation | Process for preparing polycyclic heterocycles having a pyran ring |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4021452A (en) | 1975-04-23 | 1977-05-03 | American Cyanamid Company | 2,5-Dihydro-2,5-dialkoxyfuran derivatives |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| US4127665A (en) | 1978-01-18 | 1978-11-28 | Pfizer Inc. | Thienohydantoin derivatives |
| US4147797A (en) * | 1978-08-11 | 1979-04-03 | Pfizer Inc. | Spiro-furanohydantoin derivatives |
| FR2459239A1 (fr) * | 1979-06-20 | 1981-01-09 | Logeais Labor Jacques | Nouveaux derives amines du benzothiazole, leur procede de preparation et leur application en therapeutique |
| GB8333512D0 (en) * | 1983-12-16 | 1984-01-25 | Erba Farmitalia | Tetrahydropyrano derivatives |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| NZ219646A (en) * | 1986-03-27 | 1990-10-26 | Merck Sharp & Dohme | Oxadiazole derivatives of azacyclics for treating cns disorders |
| PH30676A (en) | 1986-07-22 | 1997-09-16 | Boehringer Ingelhein Kg | Hetrazepine compounds which have useful pharmaceutical utility |
| PT90001B (pt) | 1988-03-16 | 1994-06-30 | Zambeletti Spa L | Processo para a preparacao de derivados heterociclicos de etilenodiamina |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| DE3827727A1 (de) | 1988-08-16 | 1990-02-22 | Boehringer Ingelheim Kg | Anellierte tetrahydropyridinessigsaeurederivate, verfahren zu deren herstellung und verwendung solcher verbindungen zur kardioprotektion |
| GB8824400D0 (en) | 1988-10-18 | 1988-11-23 | Glaxo Group Ltd | Chemical compounds |
| EP0368175A1 (de) | 1988-11-06 | 1990-05-16 | Boehringer Ingelheim Kg | 3S,7S-3-(Morpholinocarbonyl)-5-(2-chlorphenyl)-7,10-dimethyl-3,4-dihydro-2H,7H-cyclopenta[4,5]thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin. |
| GB8827479D0 (en) | 1988-11-24 | 1988-12-29 | Zambeletti Spa L | Novel compounds |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| EP0416740A3 (en) | 1989-08-08 | 1991-08-28 | Beecham Group P.L.C. | Novel compounds with renin-inhibiting activity |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| GB8926560D0 (en) | 1989-11-24 | 1990-01-17 | Zambeletti Spa L | Pharmaceuticals |
| US5032598A (en) | 1989-12-08 | 1991-07-16 | Merck & Co., Inc. | Nitrogens containing heterocyclic compounds as class III antiarrhythmic agents |
| GB8927872D0 (en) | 1989-12-08 | 1990-02-14 | Beecham Group Plc | Pharmaceuticals |
| JPH03223277A (ja) * | 1989-12-29 | 1991-10-02 | Yoshitomi Pharmaceut Ind Ltd | ベンゾチオフェン誘導体 |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| ZA912744B (en) | 1990-03-23 | 1992-02-26 | Zambeletti Spa L | Pharmaceuticals |
| JPH049367A (ja) | 1990-04-26 | 1992-01-14 | Zeria Pharmaceut Co Ltd | アリールアルカノイル誘導体，該化合物の製造中間体及びそれらを含有する医薬 |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| GB9018139D0 (en) * | 1990-08-17 | 1990-10-03 | Pfizer Ltd | Therapeutic agents |
| NZ240155A (en) | 1990-10-29 | 1992-10-28 | Ishihara Sangyo Kaisha | Heterocyclyl acyl and (hexahydro) indanyl acyl substituted hydrazine derivatives, preparation thereof and pesticidal compositions |
| DE4104257A1 (de) | 1991-02-13 | 1992-08-20 | Boehringer Ingelheim Kg | Verwendung von anellierten tetrahydropyridinessigsaeurederivaten fuer die behandlung neurologischer erkrankungen |
| GB9104839D0 (en) | 1991-03-07 | 1991-04-17 | Zambeletti Spa L | Novel compounds |
| NZ243065A (en) | 1991-06-13 | 1995-07-26 | Lundbeck & Co As H | Piperidine derivatives and pharmaceutical compositions |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| PH31294A (en) | 1992-02-13 | 1998-07-06 | Thomae Gmbh Dr K | Benzimidazolyl derivatives, pharmaceutical compositions containing these compounds and process for preparing them. |
| JP3223277B2 (ja) | 1992-04-10 | 2001-10-29 | カシオ計算機株式会社 | 楽音制御装置 |
| FR2692264B1 (fr) | 1992-06-12 | 1994-08-05 | Adir | Nouvelles piperazines 1,4-disubstituees, leur procede de preparation et les compositions pharmaceutiques les contenant. |
| IT1255178B (it) * | 1992-06-26 | 1995-10-20 | Pierrel Spa | N(eter0)-aril-n(etero)-tetralinalchil piperazine aventi attivita' serotoninergica,dopaminergica e adrenergica |
| DE59308842D1 (de) | 1992-12-02 | 1998-09-10 | Ciba Geigy Ag | Selektiv-herbizides Mittel |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| TW334423B (en) * | 1993-10-22 | 1998-06-21 | Hoffmann La Roche | Tricyclic 1-aminoethylpyrrole-derivatives |
| JP3163068B2 (ja) | 1993-12-27 | 2001-05-08 | 日本建工株式会社 | 野縁取付け金具 |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| FR2723091B1 (fr) | 1994-07-29 | 1996-11-08 | Esteve Labor Dr | Tetrahydropyridine-(6,4-hydroxypiperidine) alkylazoles |
| FR2734819B1 (fr) | 1995-05-31 | 1997-07-04 | Adir | Nouveaux composes de la piperazine, de la piperidine et de la 1,2,5,6-tetrahydropyridine, leur procede de preparation et les compositions pharmaceutiques les contenant |
| WO1999046267A1 (en) | 1998-03-12 | 1999-09-16 | Novo Nordisk A/S | Modulators of protein tyrosine phosphatases (ptpases) |
| US6262044B1 (en) * | 1998-03-12 | 2001-07-17 | Novo Nordisk A/S | Modulators of protein tyrosine phosphatases (PTPASES) |
| EP1080068A1 (en) * | 1998-03-12 | 2001-03-07 | Novo Nordisk A/S | Modulators of protein tyrosine phosphatases |
| BR9908726A (pt) * | 1998-03-12 | 2000-11-21 | Novo Nordisk As | Composto, composiçãp farmacêutica, uso de um composto, e, processos para tratamento do diabete do tipo i e de disfunções imunes, para fabricação de um medicamento, e, para preparação de um composto |
| AU6325599A (en) | 1998-10-21 | 2000-05-08 | Dr. Reddy's Research Foundation | New compounds, their preparation and use |
| BR9917047A (pt) | 1998-12-14 | 2002-07-30 | Fujisawa Pharmaceutical Co | Composto de piperazina, método para prepará-lo, composição farmacêutica contendo-o e seu uso |
| AU776276B2 (en) | 1999-01-19 | 2004-09-02 | Neurosearch A/S | Fused heterocyclic compounds and their use in the treatment of neurodegenerative diseases |
| US6313309B1 (en) * | 1999-04-05 | 2001-11-06 | Ortho-Mcneil Pharmaceutical, Inc. | 4-thionaphthyl—1H—imidazoles which are usefulα22-adrenoceptoR agonists/ antagonists |
| AU4589800A (en) | 1999-05-05 | 2000-11-21 | Darwin Discovery Limited | 9-(1,2,3,4-tetrahydronaphthalen-1-yl)-1,9-dihydropurin-6-one derivatives as pde7inhibitors |
| EP1196160B1 (en) | 1999-07-02 | 2005-12-21 | Warner-Lambert Company Llc | A synergistic combination: gabapentin and pregabalin |
| EP1214060A2 (en) | 1999-09-10 | 2002-06-19 | Novo Nordisk A/S | Method of inhibiting protein tyrosine phosphatase 1b and/or t-cell protein tyrosine phosphatase and/or other ptpases with an asp residue at position 48 |
| WO2001019831A1 (en) | 1999-09-10 | 2001-03-22 | Novo Nordisk A/S | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases) |
| WO2001032610A1 (en) | 1999-10-29 | 2001-05-10 | Kaken Pharmaceutical Co., Ltd. | Urea derivative, process for producing the same, and medicine containing the urea derivative |
| AR030537A1 (es) | 1999-11-05 | 2003-08-27 | Abbott Lab | Acidos quinolincarboxilicos y naftiridincarboxilico antibacterianos |
| ES2213996T3 (es) * | 1999-12-08 | 2004-09-01 | Centre National De La Recherche Scientifique (Cnrs) | Uso de himenialdisina o sus derivados en la fabricacion de medicamentos. |
| AU2001277731A1 (en) | 2000-08-09 | 2002-02-18 | Welfide Corporation | Fused bicyclic amide compounds and medicinal use thereof |
| AU2001286191A1 (en) | 2000-09-12 | 2002-03-26 | Sankyo Company, Limited | Quinolizine derivatives |
| WO2002102387A1 (en) | 2001-06-18 | 2002-12-27 | H. Lundbeck A/S | Treatment of neuropathic pain |
| US20040180883A1 (en) * | 2001-07-11 | 2004-09-16 | Jeremy Gilmore | Pharmaceutical compounds with serotonin receptor activity |
| EP1409476B1 (en) * | 2001-07-11 | 2004-12-15 | Eli Lilly And Company | Pharmaceutical compounds with serotonin receptor activity |
| JP5039268B2 (ja) | 2001-10-26 | 2012-10-03 | アベンティス・ファーマスーティカルズ・インコーポレイテツド | ベンゾイミダゾールおよび類縁体および蛋白キナーゼ阻害剤としてのその使用 |
| JP2003261566A (ja) | 2002-03-11 | 2003-09-19 | Sankyo Co Ltd | キノリジンを含有する医薬 |
| TW200930291A (en) * | 2002-04-29 | 2009-07-16 | Bayer Cropscience Ag | Pesticidal heterocycles |
| US7276522B2 (en) | 2002-05-21 | 2007-10-02 | Allergan, Inc. | 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones, 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds |
| US7091232B2 (en) | 2002-05-21 | 2006-08-15 | Allergan, Inc. | 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds |
| US7358269B2 (en) | 2002-05-21 | 2008-04-15 | Allergan, Inc. | 2-((2-Thioxo-2,3-dihydro-1H-imidazol-4-yl)methyl)-3,4-dihydronapthalen-1(2H)-one |
| US7323485B2 (en) | 2002-05-21 | 2008-01-29 | Allergan, Inc. | 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds |
| SE0202134D0 (sv) | 2002-07-08 | 2002-07-08 | Astrazeneca Ab | Therapeutic agents |
| US7778779B2 (en) | 2002-10-16 | 2010-08-17 | Isis Innovation Limited | Method of identifying a chemical entity which is a hydroxylase modulator |
| DE10252667A1 (de) * | 2002-11-11 | 2004-05-27 | Grünenthal GmbH | Spirocyclische Cyclohexan-Derivate |
| CN101353321A (zh) * | 2002-11-21 | 2009-01-28 | 辉瑞产品公司 | 3-氨基-哌啶衍生物及其制备方法 |
| EP1587482A4 (en) | 2003-01-31 | 2010-08-25 | Technion Res & Dev Foundation | INFLAMMATORY COMPOSITIONS AND ITS USES |
| WO2004078723A1 (ja) | 2003-03-07 | 2004-09-16 | Santen Pharmaceutical Co. Ltd. | ４－ピリジルアルキルチオ基を置換基として有する新規化合物 |
| JP2004269449A (ja) | 2003-03-11 | 2004-09-30 | Ishihara Sangyo Kaisha Ltd | ベンズアミド誘導体、それらの製造方法及びそれらを含有する有害生物防除剤 |
| US7205318B2 (en) | 2003-03-18 | 2007-04-17 | Bristol-Myers Squibb Company | Lactam-containing cyclic diamines and derivatives as a factor Xa inhibitors |
| WO2004087680A1 (en) | 2003-03-31 | 2004-10-14 | Taisho Pharmaceutical Co., Ltd. | Novel quinazoline derivatives and methods of treatment related to the use thereof |
| JP2005145859A (ja) | 2003-11-13 | 2005-06-09 | Nippon Steel Chem Co Ltd | 脱水素化方法及び芳香族複素環化合物の製造方法 |
| DE10360793A1 (de) * | 2003-12-23 | 2005-07-28 | Grünenthal GmbH | Spirocyclische Cyclohexan-Derivate |
| AU2005208938A1 (en) | 2004-01-29 | 2005-08-11 | Elixir Pharmaceuticals, Inc | Anti-viral therapeutics |
| DE102004004974A1 (de) | 2004-01-31 | 2005-08-18 | Aventis Pharma Deutschland Gmbh | Thieno-Iminosäure-Derivate als Inhibitoren von Matrix-Metalloproteinasen |
| KR100553398B1 (ko) | 2004-03-12 | 2006-02-16 | 한미약품 주식회사 | 티에노[3,2-ｃ]피리딘 유도체의 제조 방법 및 이에사용되는 중간체 |
| JP2008508314A (ja) | 2004-07-28 | 2008-03-21 | アイアールエム・リミテッド・ライアビリティ・カンパニー | ステロイドホルモン核内受容体のモジュレーターとしての化合物および組成物 |
| SE0401970D0 (sv) | 2004-08-02 | 2004-08-02 | Astrazeneca Ab | Novel compounds |
| SE0401971D0 (sv) | 2004-08-02 | 2004-08-02 | Astrazeneca Ab | Piperidne derivatives |
| EP1634873A1 (en) | 2004-08-27 | 2006-03-15 | Laboratorios Del Dr. Esteve, S.A. | Sigma receptor inhibitors |
| FR2875230A1 (fr) | 2004-09-13 | 2006-03-17 | Sanofi Aventis Sa | Derives de pyrazole condense, leur preparation et leur application en therapeutique |
| JP2006117568A (ja) | 2004-10-20 | 2006-05-11 | Mitsubishi Pharma Corp | チオフェン環を有する新規アミド誘導体及びその医薬としての用途 |
| WO2006053274A2 (en) | 2004-11-15 | 2006-05-18 | Bristol-Myers Squibb Company | 2-amino-1-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors |
| CN101120002A (zh) * | 2005-02-17 | 2008-02-06 | 惠氏公司 | 环烷基稠合的吲哚、苯并噻吩、苯并呋喃和茚衍生物 |
| CN101203512A (zh) | 2005-04-22 | 2008-06-18 | 第一三共株式会社 | 杂环化合物 |
| WO2007001939A1 (en) | 2005-06-27 | 2007-01-04 | Janssen Pharmaceutica N.V. | Tetrahydro-pyranopyrazole compounds displaying cannabinoid modulating activities |
| KR20080030630A (ko) | 2005-06-27 | 2008-04-04 | 이 아이 듀폰 디 네모아 앤드 캄파니 | 전기 전도성 중합체 조성물 |
| BRPI0615524A2 (pt) | 2005-07-11 | 2010-04-06 | Devgen Nv | derivados da amida como inibidores da quinase |
| US8846742B2 (en) | 2006-02-14 | 2014-09-30 | The Trustees Of Columbia University In The City Of New York | Neuronal pain pathway modulators |
| JP2009528999A (ja) | 2006-02-21 | 2009-08-13 | アンプラ ファーマシューティカルズ インコーポレイテッド | Ｃｂ１アンタゴニストおよび逆アゴニスト |
| EP1829869A1 (en) * | 2006-03-02 | 2007-09-05 | Laboratorios Del Dr. Esteve, S.A. | 4,5,6,7-Tetrahydrobenzo[b]thiophene derivatives and their use as sigma receptor ligands |
| JPWO2007126041A1 (ja) * | 2006-04-28 | 2009-09-10 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ベンゾイソオキサゾール化合物 |
| AU2007305269A1 (en) | 2006-10-04 | 2008-04-10 | Schering Corporation | Bicyclic and tricyclic derivatives as thrombin receptor antagonists |
| US7960569B2 (en) | 2006-10-17 | 2011-06-14 | Bristol-Myers Squibb Company | Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions |
| US20100137294A1 (en) | 2006-11-15 | 2010-06-03 | Genetic Technologies Limited | Compounds, compositions and methods for controlling invertebrate pests |
| WO2009008906A2 (en) | 2007-02-06 | 2009-01-15 | The Trustees Of The University Of Pennsylvania | Therapeutic compounds for blocking dna synthesis of pox viruses |
| US7598417B2 (en) | 2007-04-12 | 2009-10-06 | Allergan, Inc. | Substituted fluoroethyl ureas as alpha 2 adrenergic agents |
| EP1982987A1 (en) * | 2007-04-16 | 2008-10-22 | Laboratorios del Dr. Esteve S.A. | Spiro-pyrano-pyrazole derivatives |
| EP1982714A1 (en) | 2007-04-16 | 2008-10-22 | Laboratorios del Dr. Esteve S.A. | Pyrano-pyrazole-amines |
| EP2020414A1 (en) | 2007-06-20 | 2009-02-04 | Laboratorios del Dr. Esteve S.A. | spiro[piperidine-4,4'-thieno[3,2-c]pyran] derivatives and related compounds as inhibitors of the sigma receptor for the treatment of psychosis |
| US8338623B2 (en) * | 2007-07-09 | 2012-12-25 | Abbvie Inc. | Compounds as cannabinoid receptor ligands |
| ES2469824T3 (es) | 2007-11-21 | 2014-06-20 | Janssen Pharmaceutica N.V. | Espiropiperidinas para su uso como inhibidores de la triptasa |
| US7973051B2 (en) | 2007-11-30 | 2011-07-05 | Hoffman-La Roche Inc. | Aminothiazoles as FBPase inhibitors for diabetes |
| JPWO2009072621A1 (ja) | 2007-12-07 | 2011-04-28 | 日産化学工業株式会社 | 置換ジヒドロアゾール化合物及び有害生物防除剤 |
| WO2009085256A1 (en) | 2007-12-27 | 2009-07-09 | Panacos Pharmaceuticals, Inc. | Anti-hiv compounds |
| CN101759710B (zh) | 2008-10-06 | 2011-10-05 | 山东轩竹医药科技有限公司 | 含有取代的氮杂环的头孢菌素衍生物 |
| US9776963B2 (en) | 2008-11-10 | 2017-10-03 | The Trustees Of The University Of Pennsylvania | Small molecule CD4 mimetics and uses thereof |
| TW201038569A (en) | 2009-02-16 | 2010-11-01 | Abbott Gmbh & Co Kg | Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy |
| AR075442A1 (es) | 2009-02-16 | 2011-03-30 | Abbott Gmbh & Co Kg | Derivados de aminotetralina, composiciones farmaceuticas que las contienen y sus usos en terapia |
| WO2011036889A1 (ja) | 2009-09-25 | 2011-03-31 | 武田薬品工業株式会社 | 複素環化合物 |
| DK2501704T3 (da) | 2009-11-16 | 2013-10-14 | Lilly Co Eli | Spiropiperidinforbindelser som oral-1-receptorantagonister |
| UA107943C2 (xx) * | 2009-11-16 | 2015-03-10 | Lilly Co Eli | Сполуки спіропіперидину як антагоністи рецептора orl-1 |
| PT3252057T (pt) | 2009-12-04 | 2024-06-04 | Sunovion Pharmaceuticals Inc | Compostos multicíclicos e métodos de utilização dos mesmos |
| WO2011081205A1 (ja) | 2009-12-28 | 2011-07-07 | 一般社団法人ファルマＩｐ | １，３，４－オキサジアゾール－２－カルボキサミド化合物 |
| EP2377850A1 (en) | 2010-03-30 | 2011-10-19 | Pharmeste S.r.l. | TRPV1 vanilloid receptor antagonists with a bicyclic portion |
| JP2013525368A (ja) | 2010-04-23 | 2013-06-20 | キネタ・インコーポレイテツド | 抗ウイルス性化合物 |
| US8883839B2 (en) | 2010-08-13 | 2014-11-11 | Abbott Laboratories | Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy |
| US9051280B2 (en) | 2010-08-13 | 2015-06-09 | AbbVie Deutschland GmbH & Co. KG | Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy |
| JP5715713B2 (ja) | 2011-03-10 | 2015-05-13 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 可溶性グアニル酸シクラーゼ活性化因子 |
| CN102731574B (zh) | 2011-03-30 | 2016-03-02 | 中国人民解放军军事医学科学院毒物药物研究所 | 噻吩并吡啶类α-胺基苄基膦酸酯、其制备方法及用途 |
| WO2013010453A1 (en) | 2011-07-15 | 2013-01-24 | Abbott Laboratories | Chemoking receptor antagonists |
| CN106537488B (zh) | 2014-07-23 | 2019-06-07 | 夏普株式会社 | 显示装置及其驱动方法 |
| CN116808023A (zh) | 2017-02-16 | 2023-09-29 | 桑诺维恩药品公司 | 治疗精神分裂症的方法 |
| MX2020008537A (es) | 2018-02-16 | 2021-01-08 | Sunovion Pharmaceuticals Inc | Sales, formas cristalinas y metodos de produccion de las mismas. |
| JP2021513972A (ja) | 2018-02-16 | 2021-06-03 | サノビオン ファーマシューティカルズ インクＳｕｎｏｖｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． | 社会的機能障害の治療方法 |
| CA3122261A1 (en) | 2018-12-06 | 2020-06-11 | Sunovion Pharmaceuticals Inc. | Methods of treating neurological and psychiatric disorders |
-
2010
- 2010-12-03 PT PT171602030T patent/PT3252057T/pt unknown
- 2010-12-03 CA CA3272595A patent/CA3272595A1/en active Pending
- 2010-12-03 KR KR1020217030661A patent/KR102505085B1/ko active Active
- 2010-12-03 NZ NZ711802A patent/NZ711802A/en unknown
- 2010-12-03 PT PT108351859T patent/PT2507245T/pt unknown
- 2010-12-03 DK DK17160203.0T patent/DK3252057T3/da active
- 2010-12-03 KR KR1020207002216A patent/KR102307413B1/ko active Active
- 2010-12-03 MX MX2013013377A patent/MX388468B/es unknown
- 2010-12-03 RU RU2018100098A patent/RU2707067C2/ru active
- 2010-12-03 KR KR1020187012385A patent/KR102074089B1/ko active Active
- 2010-12-03 AU AU2010325925A patent/AU2010325925B2/en active Active
- 2010-12-03 KR KR1020177023257A patent/KR101855471B1/ko active Active
- 2010-12-03 CN CN201080062822.2A patent/CN102762575B/zh active Active
- 2010-12-03 KR KR1020167017387A patent/KR101772834B1/ko active Active
- 2010-12-03 KR KR1020127017294A patent/KR101637247B1/ko active Active
- 2010-12-03 NZ NZ731621A patent/NZ731621A/en unknown
- 2010-12-03 MX MX2012006326A patent/MX2012006326A/es active IP Right Grant
- 2010-12-03 KR KR1020157019665A patent/KR101637246B1/ko active Active
- 2010-12-03 EP EP10835185.9A patent/EP2507245B1/en active Active
- 2010-12-03 CN CN201610836552.5A patent/CN106883246B/zh active Active
- 2010-12-03 CN CN202010422479.3A patent/CN111560025A/zh active Pending
- 2010-12-03 CA CA2781716A patent/CA2781716A1/en active Pending
- 2010-12-03 SG SG10201401661RA patent/SG10201401661RA/en unknown
- 2010-12-03 NZ NZ767139A patent/NZ767139A/en unknown
- 2010-12-03 DK DK10835185.9T patent/DK2507245T3/en active
- 2010-12-03 SG SG10201510665WA patent/SG10201510665WA/en unknown
- 2010-12-03 ES ES17160203T patent/ES2978959T3/es active Active
- 2010-12-03 BR BR112012013431-0A patent/BR112012013431B1/pt active IP Right Grant
- 2010-12-03 WO PCT/US2010/058884 patent/WO2011069063A2/en not_active Ceased
- 2010-12-03 CN CN202410181638.3A patent/CN118165002A/zh active Pending
- 2010-12-03 JP JP2012542219A patent/JP5778168B2/ja active Active
- 2010-12-03 EP EP17160203.0A patent/EP3252057B1/en active Active
- 2010-12-03 ES ES10835185.9T patent/ES2625330T3/es active Active
- 2010-12-03 RU RU2012127770/04A patent/RU2557059C2/ru active
- 2010-12-03 NZ NZ600008A patent/NZ600008A/en unknown
- 2010-12-03 NZ NZ626068A patent/NZ626068A/en unknown
- 2010-12-03 FI FIEP17160203.0T patent/FI3252057T3/fi active
- 2010-12-03 BR BR122021013836-2A patent/BR122021013836B1/pt active IP Right Grant
- 2010-12-03 CN CN201410333332.1A patent/CN104193761B/zh active Active
- 2010-12-03 US US13/513,176 patent/US8710245B2/en active Active
- 2010-12-03 IL IL272376A patent/IL272376B2/en unknown
- 2010-12-03 SG SG2012040895A patent/SG181498A1/en unknown
- 2010-12-03 RU RU2015119926A patent/RU2641648C1/ru active
-
2012
- 2012-05-15 ZA ZA2012/03533A patent/ZA201203533B/en unknown
- 2012-06-01 MX MX2020012825A patent/MX2020012825A/es unknown
- 2012-06-04 IL IL220173A patent/IL220173A0/en active IP Right Grant
-
2014
- 2014-03-12 US US14/205,859 patent/US9351954B2/en active Active
- 2014-12-15 JP JP2014253082A patent/JP5710064B1/ja active Active
-
2015
- 2015-06-09 HK HK15105471.0A patent/HK1212969A1/zh unknown
- 2015-07-08 JP JP2015136603A patent/JP6005807B2/ja active Active
- 2015-11-24 US US14/950,834 patent/US10085968B2/en active Active
- 2015-12-10 IL IL243021A patent/IL243021B/en active IP Right Grant
- 2015-12-10 IL IL243019A patent/IL243019B/en active IP Right Grant
- 2015-12-10 IL IL243018A patent/IL243018B/en active IP Right Grant
- 2015-12-10 IL IL243015A patent/IL243015B/en active IP Right Grant
-
2016
- 2016-01-27 AU AU2016200448A patent/AU2016200448C1/en active Active
- 2016-07-01 JP JP2016131247A patent/JP6028310B1/ja active Active
- 2016-09-29 JP JP2016191898A patent/JP6297655B2/ja active Active
-
2017
- 2017-10-20 AU AU2017248551A patent/AU2017248551B2/en active Active
-
2018
- 2018-02-21 JP JP2018028819A patent/JP2018104454A/ja active Pending
- 2018-08-30 US US16/117,450 patent/US20190125722A1/en not_active Abandoned
-
2020
- 2020-02-14 US US16/791,118 patent/US10894033B2/en active Active
- 2020-06-24 JP JP2020108727A patent/JP7104746B2/ja active Active
- 2020-11-19 US US16/952,401 patent/US20210267938A1/en not_active Abandoned
-
2022
- 2022-01-13 US US17/574,702 patent/US20220387382A1/en not_active Abandoned
-
2024
- 2024-01-18 US US18/416,065 patent/US20240358675A1/en not_active Abandoned
-
2025
- 2025-10-10 US US19/354,929 patent/US20260034093A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018104454A5 (enExample) | ||
| RU2012127770A (ru) | Полициклические соединения и способы их применения | |
| JP2016508142A5 (enExample) | ||
| JP2018058890A5 (enExample) | ||
| JP2014505690A5 (enExample) | ||
| JP2014526469A5 (enExample) | ||
| JP2016155815A5 (enExample) | ||
| JP2014515008A5 (enExample) | ||
| JP2010523651A5 (enExample) | ||
| JP2008524262A5 (enExample) | ||
| HRP20090640T1 (hr) | Kristalinični oblici (r)-8-kloro-1-metil-2,3,4,5-tetrahidro-1h-3-benzazepin hidroklorida | |
| RU2018130727A (ru) | Органические соединения | |
| HRP20140380T1 (hr) | N-oksidni i/ili di-n-oksidni derivati stabilizatora/modulatora dopaminskog receptora koji pokazuju poboljšane profile kardiovaskularnih nuspojava | |
| JP2013507371A5 (enExample) | ||
| JP2013526615A5 (enExample) | ||
| JP2007516941A5 (enExample) | ||
| JP2021519267A5 (enExample) | ||
| JP2013507374A5 (enExample) | ||
| JP2013519684A5 (enExample) | ||
| JP2013507369A5 (enExample) | ||
| CO7350619A2 (es) | Compuestos heteroaromáticos y su uso como ligandos d1 de dopamina | |
| MX373319B (es) | Derivados de hexahidro-[1-4]diazepino[6,7,1-hi]indol-8-carboxamida como agonistas del receptor 5-ht2c y el uso de los mismos en el tratamiento de enfermedades relacionadas con dicho receptor. | |
| MX351918B (es) | Derivados heterociclicos de amina. | |
| EA201391787A1 (ru) | Производные пиразола | |
| JP2012526832A5 (enExample) |